Quince Therapeutics, Inc.
QNCX
$3.69
$0.319.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.83% | -30.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.85% | -23.50% | |||
| Operating Income | -14.85% | 23.50% | |||
| Income Before Tax | 15.61% | -6.67% | |||
| Income Tax Expenses | -168.66% | 42.55% | |||
| Earnings from Continuing Operations | 16.24% | -6.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.24% | -6.78% | |||
| EBIT | -14.85% | 23.50% | |||
| EBITDA | -14.89% | 23.58% | |||
| EPS Basic | 27.52% | -0.53% | |||
| Normalized Basic EPS | 37.03% | -11.54% | |||
| EPS Diluted | 27.52% | -0.53% | |||
| Normalized Diluted EPS | 37.03% | -11.54% | |||
| Average Basic Shares Outstanding | 15.56% | 6.25% | |||
| Average Diluted Shares Outstanding | 15.56% | 6.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||